Solar Pharma’s key merchandise/income segments embrace Prescription drugs and Different Working Income for the yr ending 31-Mar-2024.
Financials
For the quarter ended 31-12-2024, the corporate has reported a Consolidated Complete Earnings of Rs 14141.08 crore, up 3.63% from final quarter Complete Earnings of Rs 13645.39 crore and up 11.96% from final yr identical quarter Complete Earnings of Rs 12630.90 crore. The corporate has reported internet revenue after tax of Rs 2917.54 crore within the newest quarter. The corporate’s high administration consists of Mr.Dilip S Shanghvi, Mr.Aalok D Shanghvi, Mr.Sudhir V Valia, Dr.Pawan Goenka, Mr.Rama Bijapurkar, Mr.Gautam Doshi, Mr.Sanjay Asher, Mr.Rolf Hoffmann. Firm has S R B C & Co. LLP as its auditors. As on 31-12-2024, the corporate has a complete of 240 crore shares excellent. Funding Rationale
A powerful specialty pipeline which incorporates Ilumya ? PsA indication, newer belongings like Fibromun and Otenaproxesul present an extended runway for development for Solar Pharma. JM Monetary expects extra such M&A offers as money pile rises. Solar Pharma’s rising specialty contribution and its outperforming India enterprise are prone to hold valuation multiples elevated within the brokerage view. They’ve a BUY name on the inventory with 12-month goal worth of Rs 2115. Promoter/FII Holdings
Promoters held 54.48 per cent stake within the firm as of , whereas FIIs owned 18.04 per cent, DIIs 18.35 per cent.
(Disclaimer: Suggestions given on this part or any reviews hooked up herein are authored by an exterior occasion. Views expressed are that of the respective authors/entities. These don’t signify the views of Financial Occasions (ET). ET doesn’t assure, vouch for, endorse any of its contents and hereby disclaims all warranties, categorical or implied, referring to the identical. Please seek the advice of your monetary adviser and search unbiased recommendation.
